BioStock: Stayble Therapeutics gives update on phase IIb study

Yesterday, the pharmaceutical development company Stayble Therapeutics updated the market regarding the ongoing phase IIb study with its candidate STA363. Due to the strict measures introduced in the participating study countries to contain the Covid-19-pandemic, the pace of patient recruitment has been unusually slow, meaning that company will have to prolong the clinical trial in order to recruit a sufficient number of patients. BioStock has spoken to CEO Andreas Gerward about the implications of updated study timetable for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/stayble-therapeutics-gives-update-on-phase-iib-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se